Teva Sets 2030 Innovative Medicines Revenue Target at $6 Billion to $7 Billion

John Kim

1 min read

Add as a preferred source on Google

Teva Sets 2030 Innovative Medicines Revenue Target at $6 Billion to $7 Billion

Teva presented the target at its Nov. 11 R&D Day.

By John Kim

Published Nov 11, 2026, 11:36 PM EST

An unmarked medicine vial stands beside capsules on a laboratory bench / TokenPost.ai

Teva set a target of $6 billion to $7 billion in revenue from innovative medicines by 2030 at its Nov. 11 R&D Day, putting a figure on one of its long-term financial goals. The figure is a target, not a reported revenue result.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.